#JPM24: Illumina reports stronger-than-expected growth, indicates Grail divestiture still in early stages

Illumina’s stock rose after reporting stronger quarterly revenue than expected, while company executives during the JP Morgan Healthcare Conference indicated cancer-testing subsidiary Grail won’t be divested imminently.

The DNA testing giant reported $1.115 billion in preliminary fourth quarter revenue, up 3% over the same period a year earlier and coming ahead of company…
Click here to view original post